Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This m...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | F&S Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666334123000107 |
| _version_ | 1797829065497903104 |
|---|---|
| author | Kristof Chwalisz, M.D., Ph.D. |
| author_facet | Kristof Chwalisz, M.D., Ph.D. |
| author_sort | Kristof Chwalisz, M.D., Ph.D. |
| collection | DOAJ |
| description | Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval. |
| first_indexed | 2024-04-09T13:14:27Z |
| format | Article |
| id | doaj.art-4be9a7574ba34e8082fc0e2d31f36784 |
| institution | Directory Open Access Journal |
| issn | 2666-3341 |
| language | English |
| last_indexed | 2024-04-09T13:14:27Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | F&S Reports |
| spelling | doaj.art-4be9a7574ba34e8082fc0e2d31f367842023-05-12T04:17:14ZengElsevierF&S Reports2666-33412023-06-01426572Clinical development of the oral gonadotropin-releasing hormone antagonist elagolixKristof Chwalisz, M.D., Ph.D.0Reprint requests: Kristof Chwalisz, M.D., Ph.D., Department of Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, Grand Rapids, Michigan.; Department of Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, Grand Rapids, MichiganElagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval.http://www.sciencedirect.com/science/article/pii/S2666334123000107ElagolixGnRH antagonistendometriosisuterine fibroids |
| spellingShingle | Kristof Chwalisz, M.D., Ph.D. Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix F&S Reports Elagolix GnRH antagonist endometriosis uterine fibroids |
| title | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_full | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_fullStr | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_full_unstemmed | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_short | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_sort | clinical development of the oral gonadotropin releasing hormone antagonist elagolix |
| topic | Elagolix GnRH antagonist endometriosis uterine fibroids |
| url | http://www.sciencedirect.com/science/article/pii/S2666334123000107 |
| work_keys_str_mv | AT kristofchwaliszmdphd clinicaldevelopmentoftheoralgonadotropinreleasinghormoneantagonistelagolix |